Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis (BALANCE)

This study has been completed.
Sponsor:
Collaborator:
United BioSource Corporation
Information provided by (Responsible Party):
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT01632540
First received: June 28, 2012
Last updated: April 14, 2014
Last verified: April 2014
  Purpose

This study will be a prospective observational study of "real world" BDP nasal aerosol users with PAR, with or without seasonal allergic rhinitis (SAR). Subjects will respond to monthly online surveys regarding rhinitis control, concomitant medical conditions, concomitant (non-AR) medications, current AR therapy, and adverse events.


Condition Intervention
Perennial Allergic Rhinitis (PAR)
Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: Investigation of the Real World Effectiveness of Beclomethasone Dipropionate (BDP) Nasal Aerosol in Perennial Allergic Rhinitis (PAR) Patients

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Change in Rhinitis Control Assessment Test (RCAT) Score [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    The RCAT will be completed each month and uses a one-week recall period. This questionnaire has six items that ask about nasal and other allergy symptoms and the control of these symptoms. Each question is responded to on a scale of 1-5. The responses are summed to evaluate a total score. A higher score (22-30) indicates that symptoms are well controlled. A lower score (5-21) indicates that rhinitis symptoms are not well controlled.


Secondary Outcome Measures:
  • Change in the Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) score [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    The TSQM-9 asks patients about their level of satisfaction or dissatisfaction with the medication they are taking in the study. The 3 subscales (effectiveness, convenience, global satisfaction) are rated separately, and there is no overall score. 7 questions have responses ranging from 1=extremely dissatisfied/difficult/inconvenient to 7=extremely satisfied/easy/convenient. 2 questions have responses ranging from 1=not at all confident/certain to 5=extremely confident/certain. Higher scores indicate greater satisfaction with the medication.

  • Change in the Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Allergy-specific (WPAI-CIQ-AS) score [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    The WPAI-CIQ-AS is a 9-item, patient-reported scale that asks about the amount of time lost from work or academic classes due to allergies, as well as the impact of allergies on performing work in the workplace or in school or attending classes. It also asks about the effect of allergies on other usual daily activities. All questions ask for recall of the last 7 days. Outcomes are expressed as impairment percentages, with higher scores indicating greater impairment and less productivity.

  • Change in the Pittsburgh Sleep Quality Index (PSQI) score [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1 month interval. 19 items generate 7 "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, daytime dysfunction. The scores of these components yield a "global score". A global score of 5 or greater indicates a poor sleeper.

  • Change in the Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) score [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    This 14-item scale covers 5 domains: activity limitations, practical problems, nose symptoms, eye symptoms, other symptoms. Responses range from 0=not troubled to 6=extremely troubled. 5 component scores and a global score are calculated. Higher scores indicate being more troubled as a result of nose/eye symptoms during the past week.

  • Change in overall healthcare utilization [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    Medical resources include in-patient care (hospitalizations, days of hospitalization), emergency room, and out-patient visits to physicians and other healthcare providers. The health services utilization survey asks for a 3 month recall and will be completed at baseline and months 3, 6, 9, and 12.

  • Change in number of non-intranasal corticosteroids (INS) medications for allergic rhinitis (AR) [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]

Enrollment: 824
Study Start Date: July 2012
Study Completion Date: February 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Perennial Allergic Rhinitis patients Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
Other Name: QNASL

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Male and female patients, at least 12 years of age, with a diagnosis of PAR for at least one year and who are newly prescribed BDP nasal aerosol.

Criteria

Inclusion Criteria:

  • Male or female
  • Age 12 years or greater at time of enrollment
  • Diagnosis of PAR for at least one year; and 2)a positive skin prick (ie, epicutaneous) or serum-specific IgE test within the past 2 years to a perennial allergen as appropriate for the location; and 3)PAR symptoms that are consistent with exposure to this allergen for at least one year
  • Uncontrolled rhinitis symptoms at the time of assessment as confirmed by a score of 21 or less on the RCAT
  • Newly prescribed BDP Nasal Aerosol (within the past 7 days but have not yet used)
  • Willing and able to complete surveys in English on a computer with internet access
  • Willing and able to provide informed consent prior to entering the study (or parent/caregiver/legal guardian if applicable)

Exclusion Criteria:

  • Current acute or chronic sinusitis or chronic purulent nasal discharge
  • Rhinitis medicamentosa or nasal structural abnormalities (including nasal polyps and clinically significant septal deviation) that significantly interfere with nasal airflow
  • Acute upper respiratory infection within the past 14 days
  • Used any pressurized metered-dose inhaler INS product (including BDP Nasal Aerosol and Ciclesonide Nasal Aerosol) within the past 90 days
  • Used any experimental therapy for AR within the past 30 days
  • Any condition which the investigator feels may interfere with the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01632540

  Hide Study Locations
Locations
United States, Alaska
Teva Investigational Site 024
Little Rock, Alaska, United States
United States, Arizona
Teva Investigational Site 028
Phoenix, Arizona, United States
United States, California
Teva Investigational Site 003
Encinitas, California, United States
Teva Investigational Site 042
Fresno, California, United States
Teva Investigational Site 006
Los Angeles, California, United States
Teva Investigational Site 017
Orange, California, United States
Teva Investigational Site 007
Palmdale, California, United States
Teva Investigational Site 021
Paramount, California, United States
Teva Investigational Site 040
Redwood City, California, United States
United States, Florida
Teva Investigational Site 014
Tallahassee, Florida, United States
Teva Investigational Site 010
Tamarac, Florida, United States
United States, Georgia
Teva Investigational Site 038
Albany, Georgia, United States
Teva Investigational Site 031
Lawrenceville, Georgia, United States
Teva Investigational Site 035
Savannah, Georgia, United States
United States, Kentucky
Teva Investigational Site 043
Fort Mitchell, Kentucky, United States
Teva Investigational Site 034
Owensboro, Kentucky, United States
United States, Louisiana
Teva Investigational Site 033
Mandeville, Louisiana, United States
United States, Maryland
Teva Investigational Site 004
Bethesda, Maryland, United States
United States, Michigan
Teva Investigational Site 037
Novi, Michigan, United States
United States, Nebraska
Teva Investigational Site 026
Omaha, Nebraska, United States
United States, New Jersey
Teva Investigational Site 002
Brick, New Jersey, United States
United States, New York
Teva Investigational Site 019
Corning, New York, United States
Teva Investigational Site 018
New York, New York, United States
Teva Investigational Site 039
Niagara Falls, New York, United States
United States, North Carolina
Teva Investigational Site 011
High Point, North Carolina, United States
Teva Investigational Site 027
Winston-Salem, North Carolina, United States
Teva Investigational Site 030
Winston-Salem, North Carolina, United States
United States, Ohio
Teva Investigational Site 013
Toledo, Ohio, United States
United States, Oregon
Teva Investigational Site 022
Ashland, Oregon, United States
Teva Investigational Site 016
Eugene, Oregon, United States
United States, Pennsylvania
Teva Investigational Site 032
Havertown, Pennsylvania, United States
Teva Investigational Site 025
Normal, Pennsylvania, United States
Teva Investigational Site 012
Pittsburgh, Pennsylvania, United States
Teva Investigational Site 023
Upland, Pennsylvania, United States
United States, Texas
Teva Investigational Site 015
Dallas, Texas, United States
Teva Investigational Site 029
Dallas, Texas, United States
Teva Investigational Site 009
Fort Worth, Texas, United States
Teva Investigational Site 020
Houston, Texas, United States
Teva Investigational Site 044
San Antonio, Texas, United States
Teva Investigational Site 041
San Antonio, Texas, United States
Teva Investigational Site 046
San Antonio, Texas, United States
Teva Investigational Site 001
Waco, Texas, United States
United States, Utah
Teva Investigational Site 005
Murray, Utah, United States
United States, Virginia
Teva Investigational Site 045
Newport News, Virginia, United States
United States, Washington
Teva Investigational Site 008
Puyallup, Washington, United States
United States, Wisconsin
Teva Investigational Site 036
Greenfield, Wisconsin, United States
Sponsors and Collaborators
Teva Pharmaceutical Industries
United BioSource Corporation
Investigators
Principal Investigator: Mark Lepore, MD Teva Pharmaceutical Industries
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier: NCT01632540     History of Changes
Other Study ID Numbers: BDP-AR-401
Study First Received: June 28, 2012
Last Updated: April 14, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Rhinitis, Allergic, Perennial
Rhinitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Respiratory Tract Infections
Beclomethasone
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on September 18, 2014